IL267353B2 - Reagents for the treatment of (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) and their uses - Google Patents
Reagents for the treatment of (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) and their usesInfo
- Publication number
- IL267353B2 IL267353B2 IL267353A IL26735319A IL267353B2 IL 267353 B2 IL267353 B2 IL 267353B2 IL 267353 A IL267353 A IL 267353A IL 26735319 A IL26735319 A IL 26735319A IL 267353 B2 IL267353 B2 IL 267353B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- set forth
- nucleic acid
- effector
- shmir
- Prior art date
Links
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 title claims description 38
- 239000003153 chemical reaction reagent Substances 0.000 title description 13
- 239000012636 effector Substances 0.000 claims description 318
- 108020004707 nucleic acids Proteins 0.000 claims description 252
- 102000039446 nucleic acids Human genes 0.000 claims description 252
- 150000007523 nucleic acids Chemical class 0.000 claims description 252
- 230000000295 complement effect Effects 0.000 claims description 237
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 214
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 72
- 239000013604 expression vector Substances 0.000 claims description 65
- 108020004999 messenger RNA Proteins 0.000 claims description 45
- 108020004414 DNA Proteins 0.000 claims description 37
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 claims description 29
- 239000002679 microRNA Substances 0.000 claims description 27
- 210000003205 muscle Anatomy 0.000 claims description 26
- 238000011144 upstream manufacturing Methods 0.000 claims description 17
- 108020004705 Codon Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 12
- 230000009368 gene silencing by RNA Effects 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 108020005029 5' Flanking Region Proteins 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 108020005065 3' Flanking Region Proteins 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 claims 24
- 108090000623 proteins and genes Proteins 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 48
- 102000004169 proteins and genes Human genes 0.000 description 48
- 230000005764 inhibitory process Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 108091027967 Small hairpin RNA Proteins 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 102000051773 human PABPN1 Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001295 alanines Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 108010054442 polyalanine Proteins 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001885 myotomy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000028499 poly(A) binding Human genes 0.000 description 1
- 108091023021 poly(A) binding Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434312P | 2016-12-14 | 2016-12-14 | |
| PCT/AU2017/051385 WO2018107228A1 (en) | 2016-12-14 | 2017-12-14 | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL267353A IL267353A (en) | 2019-08-29 |
| IL267353B1 IL267353B1 (en) | 2023-08-01 |
| IL267353B2 true IL267353B2 (en) | 2023-12-01 |
Family
ID=62557655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL267353A IL267353B2 (en) | 2016-12-14 | 2017-12-14 | Reagents for the treatment of (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) and their uses |
| IL304674A IL304674B2 (en) | 2016-12-14 | 2017-12-14 | Reagents for treating Oculopharyngeal Muscular Dystrophy (OPMD) and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304674A IL304674B2 (en) | 2016-12-14 | 2017-12-14 | Reagents for treating Oculopharyngeal Muscular Dystrophy (OPMD) and their uses |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11142765B2 (enExample) |
| EP (1) | EP3555294A4 (enExample) |
| JP (2) | JP7233149B2 (enExample) |
| KR (2) | KR102495222B1 (enExample) |
| CN (2) | CN110382698B (enExample) |
| AU (2) | AU2017377661B2 (enExample) |
| CA (1) | CA3047154A1 (enExample) |
| IL (2) | IL267353B2 (enExample) |
| MX (2) | MX2019007110A (enExample) |
| RU (1) | RU2763319C2 (enExample) |
| WO (1) | WO2018107228A1 (enExample) |
| ZA (1) | ZA202106827B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102495222B1 (ko) | 2016-12-14 | 2023-02-09 | 베니텍 아이피 홀딩스 아이엔씨. | 안구인두근위축증 (opmd)의 치료제 및 이의 사용 |
| EP3866859A4 (en) * | 2018-10-17 | 2023-08-09 | Benitec IP Holdings Inc. | METHODS OF TREATMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) |
| CA3130221A1 (en) | 2019-02-28 | 2020-09-03 | Benitec IP Holdings Inc. | Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd) |
| AU2020414441A1 (en) * | 2019-12-23 | 2022-08-18 | Versameb Ag | Compositions and methods for simultaneously modulating expression of genes |
| WO2026011009A1 (en) * | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Compositions and methods for muscle disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0211111A (pt) * | 2001-07-12 | 2004-06-22 | Univ Massachusetts | Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula |
| EP1783645A1 (en) * | 2005-11-08 | 2007-05-09 | Actigenics | Methods for the identification of microRNA and their applications in research and human health |
| WO2008092935A2 (en) * | 2007-01-31 | 2008-08-07 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same |
| DK2164967T3 (en) * | 2007-05-31 | 2015-10-19 | Univ Iowa Res Found | Reduction of off-target rna interferenstoksicitet |
| WO2010105372A1 (en) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis c virus expression |
| EP2814514B1 (en) * | 2012-02-16 | 2017-09-13 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| WO2014077693A1 (en) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| WO2014107763A1 (en) * | 2013-01-08 | 2014-07-17 | Benitec Biopharma Limited | Age-related macular degeneration treatment |
| AU2017250017B2 (en) * | 2016-04-14 | 2022-12-22 | Benitec IP Holdings Inc. | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
| KR102495222B1 (ko) * | 2016-12-14 | 2023-02-09 | 베니텍 아이피 홀딩스 아이엔씨. | 안구인두근위축증 (opmd)의 치료제 및 이의 사용 |
-
2017
- 2017-12-14 KR KR1020197019981A patent/KR102495222B1/ko active Active
- 2017-12-14 IL IL267353A patent/IL267353B2/en unknown
- 2017-12-14 US US16/469,992 patent/US11142765B2/en active Active
- 2017-12-14 CN CN201780086338.5A patent/CN110382698B/zh active Active
- 2017-12-14 AU AU2017377661A patent/AU2017377661B2/en active Active
- 2017-12-14 IL IL304674A patent/IL304674B2/en unknown
- 2017-12-14 KR KR1020237003441A patent/KR102667867B1/ko active Active
- 2017-12-14 JP JP2019532105A patent/JP7233149B2/ja active Active
- 2017-12-14 CN CN202410482087.4A patent/CN118421624A/zh active Pending
- 2017-12-14 EP EP17882179.9A patent/EP3555294A4/en active Pending
- 2017-12-14 CA CA3047154A patent/CA3047154A1/en active Pending
- 2017-12-14 WO PCT/AU2017/051385 patent/WO2018107228A1/en not_active Ceased
- 2017-12-14 RU RU2019121950A patent/RU2763319C2/ru active
- 2017-12-14 MX MX2019007110A patent/MX2019007110A/es unknown
-
2019
- 2019-06-14 MX MX2024003643A patent/MX2024003643A/es unknown
-
2021
- 2021-09-01 US US17/463,923 patent/US11932852B2/en active Active
- 2021-09-17 ZA ZA2021/06827A patent/ZA202106827B/en unknown
-
2023
- 2023-02-17 JP JP2023023159A patent/JP7431359B2/ja active Active
- 2023-08-28 AU AU2023222827A patent/AU2023222827B2/en active Active
Non-Patent Citations (7)
| Title |
|---|
| ANVAR, S.Y. ET AL.,, A DECLINE IN PABPN1 INDUCES PROGRESSIVE MUSCLE WEAKNESS IN OCULOPHARYNGEAL MUSCLE DYSTROPHY AND IN MUSCLE AGAIN, 1 June 2013 (2013-06-01) * |
| APPONI, L.H. ET AL.,, LOSS OF NUCLEAR POLY(A)-BINDING PROTEIN 1 CAUSES DEFECTS IN MYOGENESIS AND MRNA BIOGENESIS, 15 March 2010 (2010-03-15) * |
| BODEN, DANIEL, ET AL., ENHANCED GENE SILENCING OF HIV-1 SPECIFIC SIRNA USING MICRORNA DESIGNED HAIRPINS., 1 February 2004 (2004-02-01) * |
| DICKSON, G. ET AL.,, GENE THERAPY RESCUES DISEASE PHENOTYPE IN THE OCULOPHARYNGEAL MUSCULAR DYSTROPHY MOUSE MODEL, 1 May 2016 (2016-05-01) * |
| FELLMANN, CHRISTOF, ET AL., AN OPTIMIZED MICRORNA BACKBONE FOR EFFECTIVE SINGLE-COPY RNAI., 26 December 2013 (2013-12-26) * |
| FOWLER, DANIEL K., ET AL., IMPROVED KNOCKDOWN FROM ARTIFICIAL MICRORNAS IN AN ENHANCED MIR-155 BACKBONE: A DESIGNER'S GUIDE TO POTENT MULTI-TARGET RNAI., 17 November 2015 (2015-11-17) * |
| KLEIN, P. ET AL.,, GENE THERAPY STRATEGY FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD, 1 January 2014 (2014-01-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267353B1 (en) | Reagents for the treatment of oculopharyngeal muscular dystrophy (opmd) and their uses | |
| Ovsepian et al. | Gene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors | |
| US20040082534A1 (en) | Treatment of melanoma by reduction in clusterin levels | |
| US20260139273A1 (en) | Synergistic Nucleic Acid Based Therapeutics and Methods of Use for Treating Genetic Disorders | |
| NZ795443A (en) | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof | |
| EP4381069A1 (en) | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 | |
| WO2023014972A2 (en) | Microrna compositions and methods of use | |
| US20220106594A1 (en) | Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) | |
| WO2017084610A1 (zh) | miR-183或其抑制剂的用途 | |
| NZ787086A (en) | Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof | |
| US20120035241A1 (en) | Use of inhibitors of plac8 activity for the modulation of adipogenesis | |
| KR101888104B1 (ko) | MET 엑손 14 스키핑 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| Olson et al. | Dual targeting of miR-208 and miR-499 in the treatment of cardiac disorders | |
| US20150050265A1 (en) | Anti-mcpip therapies for ocular neovascularization | |
| HK1161269A (en) | Use of inhibitors of plac8 activity for the modulation of adipogenesis |